What changed in this filing

/stocks — the workspaceLOADING

Item 3. Legal Proceedings

2024-02-16 compared with 2023-02-17 · 25 added, 58 removed, 64 unchanged (56% of the section changed)

10 unchanged sentences

In addition, in December 2021, a purported class of Canadian preterm infants filed suit in British Columbia and, in October 2022, a purported class of Israeli preterm infants filed suit in Tel Aviv, both of which make similar allegations as those made in the United States against Abbott.

These plaintiffs seek various damages, including punitive damages.

These plaintiffs seek various damages.

In January 2024, the Israeli lawsuit was dismissed without prejudice.

Many of the lawsuits name another infant formula manufacturer as a co-defendant.

9 unchanged sentences

District Court for the District of Delaware alleging that DexCom breached the parties' 2014 Settlement and License Agreement by asserting infringement of patents against Abbott that DexCom previously licensed to Abbott.

In the U.S., DexCom’s patent infringement case is stayed pending resolution of Abbott’s breach of license case, which is currently set for trial on July 10, 2023.

Abbott’s U.S.

patent infringement trial against DexCom is currently scheduled for October 23, 2023.

In July 2023, Abbott was found to have a license to certain of DexCom’s patents in Abbott’s breach of contract suit.

In November 2023, the U.S.

Patent and Trademark Office found some of DexCom’s asserted patent claims invalid.

Throughout 2023, Abbott and DexCom filed additional patent infringement actions in the U.S., Germany, the U.K., Spain, and the Unified Patent Court.

DexCom’s first U.S.

patent infringement trial on its remaining claims is scheduled for March 2025.

Abbott’s first U.S.

patent infringement trial against DexCom is scheduled for March 2024.

In November 2022, Abbott learned that the United States Department of Justice, through the United States Attorney’s Office for the Western District of Michigan, is conducting a criminal investigation related to Abbott’s manufacturing of infant formula.

1 unchanged sentence

In January 2023, Abbott received a civil investigative demand from the United States Federal Trade Commission seeking information in connection with its investigation of companies who participate in bids for Women, Infants, and Children infant formula contracts.

In addition, multiple civil lawsuits have been filed against Abbott regarding Abbott’s manufacturing of certain powder infant formula products.

In addition, multiple civil lawsuits have been filed against Abbott relating to Abbott’s manufacturing of certain powder infant formula products.

MINE SAFETY DISCLOSURES

16 unchanged sentences

Elected Corporate Officer — 2012.

2015 to present — Executive Vice President, Ventures.

Elected Corporate Officer — 2006.

Earnhardt, 54

2019 to present — Executive Vice President, Medical Devices.

2023 to present — Executive Vice President and Group President, Medical Devices.

2019 to 2023 — Executive Vice President, Medical Devices.

2008 to 2019 — President, CEO, and Director, Intersect ENT (a medical technology company focused on developing treatments for ear, nose and throat conditions).

1 unchanged sentence

Funck, Jr., 62

2020 to present — Executive Vice President, Finance and Chief Financial Officer.

2023 to present — Executive Vice President, Finance.

2020 to 2023 — Executive Vice President, Finance and Chief Financial Officer.

2018 to 2020 — Senior Vice President, Finance and Controller.

1 unchanged sentence

Elected Corporate Officer — 2005.

2019 to present — Executive Vice President, Core Diagnostics.

2008 to 2019 — Vice President, Nutrition, Supply Chain.

Elected Corporate Officer — 2008.

Joseph Manning, 54

2021 to present — Executive Vice President, Nutritional Products.

2017 to 2021 — Senior Vice President, International Nutrition.

Elected Corporate Officer — 2015.

2019 to present — Executive Vice President, Human Resources.

1 unchanged sentence

Elected Corporate Officer — 2019.

2023 to present — Executive Vice Presi dent, Core Diagnostics.

2021 to 2023 — Senior Vice Presi dent, Rapid Diagnostics.

2017 to 2021 — Vice President, Transfusion Medicine.

Elected Corporate Officer — 2017 .

Daniel Salvadori, 45

6 unchanged sentences

Elected Corporate Officer — 2015.

2020 to present — Senior Vice President, Core Laboratory Diagnostics, Commercial Operations.

2017 to 2020 —Vice President, Diagnostics, Commercial Operations, Europe, Middle East and Africa.

Elected Corporate Officer — 2017.

Christopher J.

2021 to present — Senior Vice President, U.S.

2017 to 2021 — Vice President, Pediatric Nutrition.

Elected Corporate Officer — 2017.

2019 to present — Senior Vice President, Structural Heart.

2017 to 2019 — Vice President, Structural Heart.

Elected Corporate Officer — 2017.

Sammy Karam, 61

2019 to present — Senior Vice President, Established Pharmaceuticals, Emerging Markets.

2014 to 2019 — Divisional Vice President, Global Marketing Commercial Execution, Established Pharmaceuticals.

Elected Corporate Officer — 2019.

Fernando Mateus, 48

2021 to present — Senior Vice Pre sident, International Nutrition.

2018 to 2021 — Divisional Vice President, EURISA, Abbott International Nutrition.

2016 to 2018 — Chief Executive Officer, Exeltis USA, Inc.

(a subsidiary of Exeltis, a women’s health company focused on respiratory, dermatology, and endocrinology).

Elected Corporate Officer — 202 1.

2021 to present — Senior Vice Presi dent, Rapid Diagnostics.

2017 to 2021 — Vice President, Transfusion Medicine.

Elected Corporate Officer — 2017 .

2021 to present — Senior Vice Pres ident, Electrophysiology.

2019 to 2021 — Senior Vice President, Electrophysiology and Heart Failure.

2017 to 2019 — Senior Vice President, Cardiac Arrhythmias and Heart Failure.

Elected Corporate Officer — 201 7.

2021 to present — Senior Vice Pres ident, Abbott Vascular.

April 2021 to July 2021 — Divisional Vice President, U.S.

Commercial, Abbott Diabetes Care.

2019 to 2021 — Divisional Vice President, Global Marketing, Abbott Vascular.

2017 to 2019 — Divisional Vice President, U.S.

Sales and Marketing Endovascular, Abbott Vascular.

Elected Corporate Officer — 202 1.

2015 to present — Senior Vi ce President, Diabetes Care.

Elected Corporate Officer — 2015.

2017 to present — Senior Vice President, Established Pharmaceuticals, Latin America.

Elected Corporate Officer — 201 7.

Woodgrift, 61

2019 to present — Senior Vice Presid ent, Cardio Rhythm Management.

2017 to 2019 — Vice President, Global Operations, Cardiovascular and Neuromodulation.

2023 to present — Senior Vice President, Finance a nd Chief Financial Officer.

2020 to 2023 — Vice President, Finance a nd Controller.

2017 to 2020 — Divisional Vice President, Controller, Medical Devices.

Elected Corporate Officer — 2020 .

McCoy, Jr., 54

2023 to present — Vice President, Finance a nd Controller.

2017 to 2020 — Divisional Vice President, Controller, Medical Devices.

2021 to 2023 — Vice President, Treasurer.

2018 to 2021 — Divisional Vice President, Controller, Rapid Diagnostics.

Elected Corporate Officer — 2021 .

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 3. Legal Proceedings